Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Drops By 80.6%

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 76,400 shares, a decrease of 80.6% from the August 15th total of 393,700 shares. Based on an average daily trading volume, of 570,500 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.4% of the company’s stock are sold short.

Entero Therapeutics Stock Down 25.0 %

Shares of Entero Therapeutics stock traded down $0.11 during trading on Thursday, hitting $0.33. 272,524 shares of the stock traded hands, compared to its average volume of 328,639. The business’s fifty day moving average is $0.64. Entero Therapeutics has a twelve month low of $0.19 and a twelve month high of $22.20. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.